

1. Bain EE, Nugent AC, Carson RE, Luckenbaugh D, Lang L, Eckelman WC, Neumeister A, Bonne O, Williams J, Gordon J, Charney DS, Drevets WC. (2004) Decreased 5-HT1A receptor binding in bipolar depression. *Biological Psychiatry*, 55:Suppl.8;636.
2. Bain EE, Nugent A, Carson RE, Lang LX, Eckelman WC, Neumeister A, Bonne O, Charney DS, Drevets WC. (2004) Reduced 5-HT1A receptor binding with F-18 - FCWAY in bipolar depression. *Neuroimage*, 22;T167-T168.
3. Cannon DM, Nugent AC, Carson RE, Williams JM, Wood S, Solorio G, Kiesewetter DO, Eckelman WC, Drevets WC. (2004) Reduced muscarinic cholinergic2 receptor binding in bipolar disorder using PET and [F-18]FP-TZTP. *Biological Psychiatry*, 55:Suppl.8;229S-230S.
4. Cannon DM, Nugent AC, Carson RE, Williams JM, Wood S, Solorio G, Kiesewetter DO, Eckelman WC, Drevets WC. (2004) Reduced muscarinic cholinergic2 receptor binding in bipolar disorder using PET and [F-18]FP-TZTP. *Neuroimage*, 22;T41-T42.
5. Floel A, Celnik P, Schaefer M, Gingert C, Garraux G, Sawaki L, Breitenstein C, Knecht S, Herscovitch P, Cohen LG. (2004) Modulation of use-dependent plasticity by Levodopa. *Human Brain Mapping Meeting*, TU17.
6. Giovacchini G, Lang LX, Ma Y, Herscovitch P, Eckelmann WC, Carson RE. (2004) Differential effects of the selective serotonin reuptake inhibitor paroxetine on raphe and cortical 5-HT1A binding: a PET study in monkeys with 18F FPWAY. *Neuroimage*, 22;T25-T26.
7. Ichise M, Cohen RM, Liow JS, Innis RB, Carson RE. (2004) Estimation of normalized distribution volume without receptor-free reference region or arterial input function: Application to the muscarinic-2 ligand F-18 FP-TZTP. *Neuroimage*, 22;T149-T150.
8. Neumeister A, Bain EE, Nugent AC, Carson RE, Bonne O, Luckenbaugh D, Eckelman WC, Herscovitch P, Charney DS, Drevets WC. (2004) Altered serotonin 1A receptor binding in panic disorder. *Biological Psychiatry*, 55:Suppl. 8;104S-105S.
9. Nugent A, Neumeister A, Drevets W, Eckelmann WC, Channing M, Herscovitch P. (2004) Human biodistribution and dosimetry of the PET benzodiazepine receptor radioligand [11C]flumazenil. *J Nucl Med*. 45(Suppl);434P.
10. Poremba A, Malloy M, Saunders RC, Kang E, Carson R, Herscovitch P, Mishkin M. (2004) FDG-PET brain imaging in rhesus monkeys during auditory delay matching to sample performance. *Soc Neurosci Abstracts*.
11. Smith CB, Schmidt K, Burlin T, Cook M, Kang J, Qin M, Sokoloff L, Saunders RC, Bacher JD, Carson R, Channing M, Eckelmann WC, Herscovitch P, Laverman P, Vuong

- BK. (2004) PET measurement of regional rates of cerebral protein synthesis with correction for recycling. Soc Neurosci Abstracts.
12. Theodore W, Giovacchini G, Toczek M, Lang L, Fraser C, Herscovitch P, Eckelman WC, Carson RE. (2004) Reduced 5-HT1A receptors in temporal lobe epilepsy: Partial volume corrected [18F]FCWAY PET. EPILEPSIA, 44:Suppl.8;50-51.
13. Theodore W, Giovacchini G, Toczek M, Bonwetsch R, Eckelman WC, Lang LX, Herscovitch P, Carson RE. (2004) The effect of carbamazepine on PET 5-HT1A ligand binding in patients with temporal lobe epilepsy. Neuroimage, 22;T162-T163.
14. Umhau J, Esposito G, Rapoport SI, Eckelman WC, Herscovitch P, Carson R, Hibbeln J, Channing M, Vuong BK, Salem N. (2004) Positron Emission Tomography imaging of incorporation of docosahexaenoic acid from plasma into brain and heart in humans. Int Soc for the Study of Fatty Acids and Lipids (ISSFAL).